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Abstract
In many tumor types serum lactate dehydrogenase (LDH) levels is an indirect marker of tumor hypoxia, neo-angiogenesis
and worse prognosis. However data about hepatocellular carcinoma (HCC) are lacking in the clinical setting of patients
undergoing transarterial-chemoembolization (TACE) in whom hypoxia and neo-angiogenesis may represent a molecular key
to treatment failure. Aim of our analysis was to evaluate the role of LDH pre-treatment levels in determining clinical
outcome for patients with HCC receiving TACE. One hundred and fourteen patients were available for our analysis. For all
patients LDH values were collected within one month before the procedure. We divided our patients into two groups,
according to LDH serum concentration registered before TACE (first: LDH#450 U/l 84 patients; second: LDH.450 U/l 30
patients). Patients were classified according to the variation in LDH serum levels pre- and post-treatment (increased: 62
patients vs. decreased 52 patients). No statistically significant differences were found between the groups for all clinical
characteristics analyzed (gender, median age, performance status ECOG, staging systems). In patients with LDH values
below 450 U/l median time to progression (TTP) was 16.3 months, whereas it was of 10.1 months in patients above the cut-
off (p=0.0085). Accordingly median overall survival (OS) was 22.4 months and 11.7 months (p=0.0049). In patients with
decreased LDH values after treatment median TTP was 12.4 months, and median OS was 22.1 months, whereas TTP was 9.1
months and OS was 9.5 in patients with increased LDH levels (TTP: p=0.0087; OS: p,0.0001). In our experience, LDH
seemed able to predict clinical outcome for HCC patients undergoing TACE. Given the correlation between LDH levels and
tumor angiogenesis we can speculate that patients with high LDH pretreatment levels may be optimal candidates for
clinical trial exploring a multimodality treatment approach with TACE and anti-VEGF inhibitors in order to improve TTP and
OS.
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Introduction
Hepatocellular carcinoma (HCC) represents the commonest
primary cancer of the liver. Incidence is increasing and HCC has
risen to become the 5th commonest malignancy worldwide and
the third leading cause of cancer related death, exceeded only by
cancers of the lung and stomach [1,2]. HCC prevalence is higher
in sub-Saharan Africa, central and Southeast Asia.
Surgery is the only potentially curative treatment for HCC. In
carefully selected patients, resection and transplantation in fact,
allow a 5 years survival ranging from 60 to 70%, and should be
considered as a first treatment option in this setting [3].
Unfortunately most patients in Western countries present with an
intermediate or advanced HCC at diagnosis with the consequent
inability to use curative treatments. These patients are therefore
candidates to palliative therapies such as arterial embolization,
chemoembolization (TACE) and systemic treatment [4]. Only
recently the molecular targeted drug, Sorafenib, has been
introduced among the therapeutic options for these patients [5–8].
TACE represents a crucial treatment option for HCC, however
comparing clinical findings resulted often hampered by the
considerable variability in patients selection criteria and modalities
of execution of therapy [9–12]. However, global results for TACE
are still unsatisfactory, with only a small proportion of patients
benefiting from these procedures. The molecular mechanism that
accounts for treatment failure is not clear [13,14]. It is possible that
some adaptive responses to hypoxia may represent a key factor for
resistance. Induction of tumor hypoxia combined with chemo-
therapy by transcatheter arterial chemoembolization has been
widely used in treating unresectable HCC.
Hypoxia represents a clinical biological mechanism for
treatment resistance in cancer cells via the formation of new
blood vessels. Furthermore, a growing body of evidence indicates
that hypoxia might actually promote cancer development.
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cancer cells and that of normal tissues. Cancer cells maintain high
aerobic glycolytic rates and produce high levels of lactate and
pyruvate, a phenomenon known historically as the Warburg effect
[15].
Lactic dehydrogenase (LDH), which is a glycolytic enzyme,
composed of four polypeptide chains, each one encoded by
separate gene (M and H), exists in various types of human tissue
and neoplasms. LDH is a key enzyme in the conversion of
pyruvate to lactate under anaerobic conditions [16]. Five isoforms
of LDH have been identified as a result of the five different
combinations of polypeptide subunits [17]. In preclinical models
up-regulation of LDH has been suggested to ensure both an
efficient anaerobic/glycolytic metabolism and a reduced depen-
dence on oxygen under hypoxic conditions in tumor cells. Altered
serum levels of LDH has also been reported in patients with HCC.
The biological link between hypoxia, LDH levels and the
tumor-driven angiogenesis pathway through the abnormal activa-
tion of the hypoxia inducible factor 1 (HIF-1) is well established.
The biological activity of HIF-1 is determined by the expression
and activity of the HIF-1a subunit [18]. HIF-1a is an essential
factor that upregulates a series of genes involved in glycolytic
energy metabolism, angiogenesis, erythropoiesis and cell survival
[19]. Hypoxia in the tumor microenvironment is sufficient to
activate HIF-dependent expression of several downregulated genes
[20]. These include genes encoding for vascular endothelial
growth factor, erythropoietin and many enzymes involved in
glucose, iron, and nucleotide metabolism [21].
Although links among these factors are well known, their
translation into clinical practice is still poorly investigated. The aim
of our analysis is to assess the prognostic role of LDH in a
population of HCC patients, treated with TACE.
Methods
Patients selection
We retrospectively analyzed a population of HCC patients,
treated with TACE (lipiodol or drug-eluting microspheres) from
2002 to 2010, at our institution. The study included all patients
consecutively treated with TACE (in our institution, patients were
treated with TACE with lipiodol from 2002 until 2006 and with
TACE with microspheres from 2007 to 2010). Patients were
classified according to ECOG PS (Eastern Cooperative Oncology
Group performance status) and were staged using different staging
systems: Child-Pugh, BCLC (Barcelona Clinic Liver Cancer),
Okuda, MELD (Model for End-Stage Liver Disease), MELD-Na
(Model for End-Stage Liver Disease – Sodium).
We recorded LDH serum levels pre- (within 1 month prior to
treatment) and post-treatment (within one month after). LDH
serum levels were determined according to IFCC (International
Federation of Clinical Chemistry and Laboratory Medicine)
method. The assay has been conducted in Our Institution
Laboratory certified for Quality control according to the present
rules in Europe (ISO 9001:2008). Patients were divided into two
groups, according to LDH serum concentration registered before
TACE. First group included patients with pretreatment
LDH#450 U/l, whereas the other group included patients with
pretreatment LDH.450 U/l. LDH serum levels cut-off has been
set to 450 U/l, because it is the upper limit of normality in blood
specimens in our Institution. Patients were, also, classified
according to any variation in LDH serum levels pre- and post-
treatment (increased vs. decreased).
The A.O.U. ‘‘Ospedali Riuniti’’ of Ancona Ethical Committee
approved the analysis. Patients gave written consent for their
clinical information to be anonymously stored in the hospital
database and used for research.
Clinical outcome evaluation and statistical analysis
Treatment response was assessed through computed tomogra-
phy (CT) and magnetic resonance imaging (MRI), alpha-
fetoprotein (a-FP) assay, performed after one month of treatment
and then every 3 months, according to the new RECIST criteria
(New Response Evaluation Criteria in Solid Tumors 1.1).
Radiological images were reviewed in double-blind by two
radiologists.
The distribution curves of survival and time to progression were
estimated using the Kaplan-Meier method. Overall survival (OS)
was calculated as the time interval between the date of the
procedure and the date of death or last follow-up. The time to
progression (TTP) was calculated as the time interval between the
date of the procedure and the date of progression or last follow-up.
The clinical variables analyzed were: gender (male vs. female),
age (#69 years vs. .69 years), ECOG PS (0–1 vs. 2–3), the Child-
Pugh score (A vs. B), BCLC stage (A vs. B–C), Okuda stage (I vs. II
vs. III), the MELD score (#10 vs. 11–15 vs. .15), the MELD-Na
score (#10 vs. 11–15 vs. .15), the type of TACE (TACE or
precision TACE; Lipiodol or drug eluting microspheres).
The association between variables was estimated using the chi-
square test. Any differences between the groups were considered
significant if the significance level was less than 0.05.
Results
One hundred and fourteen patients were available for our
analysis: 98 (86%) males and 16 (14%) females. Median age was 69
years (range 49–89) (Table 1). Eighty-four patients (74%) showed
pretreatment LDH serum levels below the cut-off, while 30 (26%)
were found above the chosen cut-off. Sixty-two patients (54%)
showed decreased LDH serum levels after treatment, while in 52
(46%) this value increased.
No statistically significant differences were found between the
groups of patients for all clinical characteristics analyzed (gender,
median age, performance status ECOG, staging systems) (Table 1).
Moreover, among the same groups, no significant differences were
found in terms of objective responses (Table 2) and according with
the type of TACE performed (lipiodol or drug-eluting micro-
spheres).
In patients with LDH values below 450 U/l median time to
progression (TTP) was 16.3 months, whereas it was of 10.1 months
in patients above the cut-off. This difference was found to be
statistically significant (p=0.0085) (Figure 1, panel 1). Accordingly
median overall survival (OS) was 22.4 months and 11.7 months in
group A and B respectively (p=0.0049) (Figure 1, panel 2). In
patients with decreased LDH values after treatment median TTP
was 12.4 months, and median OS was 22.1 months, whereas TTP
was 9.1 months and OS was 9.5 in patients with increased LDH
levels (TTP: p=0.0087 Figure 1, panel 3; OS: p,0.0001 Figure 1,
panel 4).
Discussion
The clinical management of HCC is becoming increasingly
challenging along with the growing availability of therapeutic
options. Moreover the typical HCC patient has, in most cases, two
different diseases, cancer and the underlying liver disease, both
heavily influencing patients clinical outcome. In this setting
patients stratification may represent a crucial factor for the choice
of the appropriate treatment strategy for the appropriate patient.
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relevant degree of heterogeneity can still be seen in the same sub-
group of patients making treatment selection highly demanding.
In our experience, LDH serum levels seemed able to predict
clinical outcome in terms of TTP and OS for HCC patients
undergoing TACE. Globally our data indicated that LDH levels
might identify patients with distinctive prognosis within the same
staging group.
These findings are in accordance with previously published
analyses suggesting a relationship between LDH levels and a worse
outcome in different tumor types.
In colorectal cancer patients LDH up-regulation was in fact
associated with an increased risk of nodal and distant metastases
and high LDH serum levels have been shown to correlate with a
decreased median overall survival [22,23].
A strong association has also been demonstrated between the
expression of LDH, in particular the LDH-5 isoform and an
aggressive phenotype in gastric cancer [24].
This apparently enhanced tumor aggressiveness often deter-
mining worse prognosis in cancer patients showing high LDH
levels has been traditionally correlated with molecular mechanism
underlying tumor hypoxia and angiogenesis.
The possible link between LDH levels and tumor angiogenesis
has been indicated in 2 different clinical trials (the CONFIRM 1 &
2 trials) investigating PTK/ZK (vatalanib), an oral inhibitor of
VEGF (vascular endothelial growth factor) receptors, in first and
second-line therapy of advanced colorectal cancer. Results from
subsequent analyses from these trials in fact evidenced an
improved median PFS with the use of PTK/ZK in patients with
high serum LDH levels, thus suggesting that tumor angiogenesis
represent a key crucial event in presence of high LDH levels
[25,26].
Increased levels of VEGF have been associated with tumor
grade and with an inferior overall survival in HCC, apparently
indicating that angiogenesis may represent a key-factor also for
these patients [27,28].
Table 1. Clinical variables examined resulted balanced between the group of patients with high lactic dehydrogenase (LDH)
serum levels (LDH.450 U/l) and those with a low value (LDH,450 U/l) and in those with a decreased or increased LDH serum level
after transarterial-chemoembolization (TACE) treatment.
Clinical Variables LDH,450 U/l LDH.450 U/l Total LDH decreased LDH increased Total
Patients 84 30 114 62 52 114
Gender Male 76 22 98 50 48 98
Female 8 8 16 12 4 16
Median Age ,69 42 12 54 30 22 52
.69 42 18 60 32 30 62
E C O G 0 2 81 03 8 2 1 1 7 3 8
1 5 62 07 6 4 1 3 5 7 6
Child-Pugh A 51 12 63 35 28 63
B 3 31 85 1 2 7 2 4 5 1
BCLC A–B 30 14 44 22 20 42
C 5 41 67 0 4 0 3 2 7 2
Okuda 1 50 15 65 38 25 63
2 3 41 54 9 2 4 2 7 5 1
MELD ,10 57 23 80 36 37 73
10–15 27 7 34 26 15 41
MELD-Na ,10 39 17 56 38 25 63
10–15 45 13 58 24 27 51
ECOG PS (Eastern Cooperative Oncology Group performance status), BCLC (Barcelona Clinic Liver Cancer), MELD (Model for End-Stage Liver Disease), MELD-Na (Model
for End-Stage Liver Disease – Sodium).
doi:10.1371/journal.pone.0032653.t001
Table 2. Objective response evaluated with RECIST criteria (New Response Evaluation Criteria in Solid Tumors 1.1), no statistically
significant difference was found between the groups of patients analyzed: lactic dehydrogenase (LDH) major or minor of 450 U/l
and LDH decreased or increased after treatment.
Objective Responce LDH,450 U/l LDH.450 U/l Total LDH decreased LDH increased Total
CR 19 5 24 13 9 22
PR 26 11 37 18 13 31
SD 19 3 22 21 14 35
PD 20 11 31 10 16 26
doi:10.1371/journal.pone.0032653.t002
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post-treatment) might correlate with clinical outcome in HCC patients.
These findings seem to suggest that the biological phenomenon
underlying LDH serum levels is a dy n a m i co n ea n dm a yb ei n f l u e n c e d
by medical treatment. Recently Kohles et al. showed a possible
prognostic role of pretreatment LDH serum levels in HCC patients
undergoing TACE [29], confirming our hypothesis. We can then
speculate that patients with high LDH pretreatment levels may be
optimal candidates for clinical trial exploring a multimodality
treatment approach including TACE and VEGF inhibitors.
After confirmation in larger analyses we believe that LDH
should be considered as a relevant clinical variable to be included
in the prognostic classification of HCC patients, with the aim to
better define the most appropriate therapeutic strategy and to
better stratify patients included in clinical trials.
Further studies testing the molecular and biological correlation
between serum LDH levels and tumor angiogenesis are needed in
both basic science and clinical arenas.
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